Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 1
2011 2
2012 1
2014 1
2015 6
2016 4
2017 2
2018 6
2019 6
2020 6
2021 2
2022 4
2023 7
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

47 results

Results by year

Filters applied: . Clear all
Page 1
Initial management approach for localized/locally advanced disease is critical to guide metastatic castration-resistant prostate cancer care.
Conteduca V, Di Tullio P, Allamprese R, Bruno G, Lolli C, Schepisi G, Rosano A, Giordano G, Garofoli M, Chiuri VE, Fratino L, Zanardi E, Galli L, Massari F, Falagario U, Rescigno P, Fornarini G, Sanguedolce F, Santini D, Procopio G, Caffo O, Carrieri G, Landriscina M, De Giorgi U. Conteduca V, et al. Among authors: zanardi e. Prostate Cancer Prostatic Dis. 2024 Feb 12. doi: 10.1038/s41391-024-00800-8. Online ahead of print. Prostate Cancer Prostatic Dis. 2024. PMID: 38347113
Untargeted lipidomics reveal association of elevated plasma C18 ceramide levels with reduced survival in metastatic castration-resistant prostate cancer patients.
Cattrini C, Manfredi M, Barboro P, Ghirimoldi M, Mennitto A, Martini V, Battioni A, Le Van M, Gobbato S, Branni C, Ayed RB, Pinato DJ, Catalano F, Zanardi E, Boccardo F, Gennari A. Cattrini C, et al. Among authors: zanardi e. Sci Rep. 2023 Oct 18;13(1):17791. doi: 10.1038/s41598-023-44157-9. Sci Rep. 2023. PMID: 37853018 Free PMC article.
Clinical outcomes of volume of disease on patients receiving enzalutamide versus abiraterone acetate plus prednisone as first-line therapy for metastatic castration-resistant prostate cancer.
Nuzzo PV, Ravera F, Saieva C, Zanardi E, Fotia G, Malgeri A, Rossetti S, Valença LB, Oliveira TM, Vauchier C, Pereira Mestre R, Modesti M, Patrikidou A, Pignata S, Procopio G, Fornarini G, De Giorgi U, Russo A, Francini E. Nuzzo PV, et al. Among authors: zanardi e. Ther Adv Med Oncol. 2023 Mar 3;15:17588359231156147. doi: 10.1177/17588359231156147. eCollection 2023. Ther Adv Med Oncol. 2023. PMID: 36895852 Free PMC article.
The Role of mpMRI in the Assessment of Prostate Cancer Recurrence Using the PI-RR System: Diagnostic Accuracy and Interobserver Agreement in Readers with Different Expertise.
Bergaglio C, Giasotto V, Marcenaro M, Barra S, Turazzi M, Bauckneht M, Casaleggio A, Sciabà F, Terrone C, Mantica G, Borghesi M, Signori A, Spina B, Piol N, Zanardi E, Fornarini G, Zawaideh JP; Uro-Oncology Disease Management Team (DMT) of the IRCCS Ospedale Policlinico San Martino Genoa, Italy. Bergaglio C, et al. Among authors: zanardi e. Diagnostics (Basel). 2023 Jan 20;13(3):387. doi: 10.3390/diagnostics13030387. Diagnostics (Basel). 2023. PMID: 36766492 Free PMC article.
Clinical impact of volume of disease and time of metastatic disease presentation on patients receiving enzalutamide or abiraterone acetate plus prednisone as first-line therapy for metastatic castration-resistant prostate cancer.
Nuzzo PV, Pederzoli F, Saieva C, Zanardi E, Fotia G, Malgeri A, Rossetti S, Valenca Bueno L, Andrade LMQS, Patrikidou A, Mestre RP, Modesti M, Pignata S, Procopio G, Fornarini G, De Giorgi U, Russo A, Francini E; SPARTACUSS Investigators. Nuzzo PV, et al. Among authors: zanardi e. J Transl Med. 2023 Feb 3;21(1):75. doi: 10.1186/s12967-022-03861-2. J Transl Med. 2023. PMID: 36737752 Free PMC article.
Oligometastatic Prostate Cancer Treated with Metastasis-Directed Therapy Guided by Positron Emission Tomography: Does the Tracer Matter?
Lanfranchi F, Belgioia L, Marcenaro M, Zanardi E, Timon G, Riondato M, Giasotto V, Zawaideh JP, Tomasello L, Mantica G, Piol N, Borghesi M, Traverso P, Satragno C, Panarello D, Scaffidi C, Romagnoli A, Rebuzzi SE, Coco A, Spina B, Morbelli S, Sambuceti G, Terrone C, Barra S, Fornarini G, Bauckneht M. Lanfranchi F, et al. Among authors: zanardi e. Cancers (Basel). 2023 Jan 3;15(1):323. doi: 10.3390/cancers15010323. Cancers (Basel). 2023. PMID: 36612319 Free PMC article.
47 results